



THE IMPACT OF PROBIOTICS ON GUT FLORA AND HEALTH

Seema Thakur^{*1}, Jashanpreet Kaur¹, Nisha Sharma¹, Neha Srivastava²¹Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Ludhiana, Punjab²School of Pharmaceutical Sciences, RIMT University, Mandi Gobindgarh, PunjabCorresponding author E- mail: seemathakur@pcte.edu.in

ARTICLE INFO

ABSTRACT

Key words:

Probiotics,
Gut Microbiota,
Dysbiosis,
Immune Modulation,
Short-Chain Fatty
Acids, Gastrointestinal
Health

Probiotics are live microorganisms that confer health benefits when administered in adequate amounts, primarily through modulation of gut microbiota composition and function. This review examines the relationship between probiotics and gut flora, emphasizing their role in maintaining gastrointestinal health, immune regulation, metabolic balance, and overall well-being. The human gut microbiota is a complex ecosystem comprising bacteria, viruses, fungi, and host cells that collectively maintain gut homeostasis. Dysbiosis, or microbial imbalance, has been associated with gastrointestinal, metabolic, autoimmune, and neuropsychiatric disorders. Probiotics influence gut microbiota by enhancing microbial diversity, producing beneficial metabolites such as short-chain fatty acids (SCFAs), strengthening intestinal barrier integrity, and modulating immune responses. Emerging evidence suggests their therapeutic potential in conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), obesity, type 2 diabetes, and mental health disorders through the gut–brain axis. This review also discusses the mechanisms of probiotic action, challenges in probiotic research, and future directions, including personalized probiotics, synbiotics, postbiotics, and microbiome engineering. Understanding strain-specific effects and individualized microbial responses is essential for optimizing probiotic interventions. Overall, probiotics represent a promising strategy for preventive and therapeutic health management; however, further evidence-based, standardized clinical studies are required to establish precise applications.

Access this article online

Website:

<https://www.jgtps.com/>

Quick Response Code:

**INTRODUCTION:**

The gastrointestinal tract (GIT) hosts a highly diverse and dynamic population of microorganisms collectively known as the gut microbiota, consisting primarily of bacteria along with viruses, fungi, and archaea (1). This microbial ecosystem performs essential physiological functions, including digestion of complex dietary components, synthesis of vitamins, immune system regulation, maintenance of intestinal barrier integrity, and metabolic homeostasis (2). The gut microbiota contributes significantly to host health by fermenting

nondigestible carbohydrates into short-chain fatty acids (SCFAs), which serve as energy sources and regulate inflammation, metabolism, and epithelial health. Disruptions in microbial balance, termed dysbiosis, have been associated with numerous disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), obesity, diabetes, autoimmune diseases, and neuropsychiatric conditions(3). Increasing evidence highlights the significance of the gut–brain axis, a bidirectional communication pathway linking

gut microbiota with neurological and psychological health.

Probiotics, defined as live microorganisms that provide health benefits when consumed in appropriate quantities, have emerged as promising modulators of gut microbiota composition and activity (4). Common probiotic strains include *Lactobacillus*, *Bifidobacterium*, *Saccharomyces boulardii*, and *Streptococcus thermophilus*. These microorganisms exert beneficial effects through competitive pathogen exclusion, production of antimicrobial substances, enhancement of epithelial barrier function, and immunomodulation.

This review aims to provide a comprehensive analysis of probiotics and their impact on gut microbiota and human health. It further explores probiotic mechanisms, therapeutic applications, challenges in current research, and future advancements such as personalized probiotic therapy and microbiome engineering (5).

RATIONALE

Common probiotic strains include *Lactobacillus* spp., *Bifidobacterium* spp., *Saccharomyces boulardii*, and *Streptococcus thermophilus*. These beneficial microorganisms exert their effects through multiple mechanisms, including competitive exclusion of pathogenic microbes, production of antimicrobial compounds, enhancement of intestinal epithelial barrier integrity, modulation of host immune responses, and synthesis of bioactive metabolites such as short-chain fatty acids (SCFAs).

This review provides a comprehensive evaluation of the role of probiotics in modulating gut microbiota and their implications for human health. It examines probiotic characteristics, mechanisms of action, therapeutic applications in gastrointestinal, metabolic, immune, and neuropsychiatric disorders, current research challenges, and emerging advancements including personalized probiotics, synbiotics, postbiotics, and microbiome engineering (6).

POTENTIAL APPLICATION OF PROBIOTICS IN VARIOUS HEALTH CONDITIONS

Probiotics, live microorganisms present in human gut (shown in fig.1) with demonstrated health benefits, have garnered significant attention for their potential applications in addressing various health conditions. These beneficial bacteria, commonly found in fermented foods and dietary supplements, are essential in regulating the intestinal microbiota and influencing diverse physiological processes.

One notable application is in digestive health, where probiotics have been studied for their ability to alleviate symptoms of conditions such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), and antibiotic-associated diarrhea. Probiotics have also shown promise in supporting the immune system, contributing to a balanced gut microbiota that helps fend off harmful pathogens (5). Beyond the gastrointestinal tract, research is exploring the potential of probiotics in addressing conditions like allergies, eczema, and respiratory infections, type 2 diabetes, highlighting their systemic impact on health. Furthermore, because the gut-brain axis indicates a link between gut microbiota and neurological function, there is increased interest in the role of probiotics in mental health. As the scientific understanding of probiotics deepens, their potential applications in diabetes continue to expand, offering a holistic approach to health that goes beyond traditional digestive benefits (7).

COMPOSITION AND FUNCTION OF GUT MICROBIOTA

The gastrointestinal tract is home to a diverse and ever-changing collection of bacteria known as the gut microbiota, primarily in the colon. Comprising bacteria, viruses, fungi, and archaea, this diverse ecosystem plays a crucial role in maintaining human health. The gut microbiota's composition is very variable and depends on a number of factors, including age, food, genetics, and environmental exposures. Functionally, the gut microbiota is involved in a multitude of essential processes. One key role is in the fermentation of dietary fibers and complex carbohydrates that are resistant to digestion in the upper gastrointestinal tract. This fermentation produces short-chain fatty acids

(SCFAs), which serve as an energy source for the host and play a role in regulating various physiological functions. The gut microbiota is also instrumental in nutrient metabolism, aiding in the absorption of certain vitamins and minerals. Furthermore, it has a role in immune system development and regulation, helping the body distinguish between harmful pathogens and beneficial microorganisms. Another significant function is the prevention of colonization by pathogenic bacteria through competition for resources and the production of antimicrobial substances (8). The gut microbiota acts as a protective barrier, supporting the overall health of the host. Recent studies have demonstrated the gut-brain axis, which is the name for the two-way communication between the gut bacteria and the central neurological system. This communication may influence various aspects of mental health, adding another layer to the multifaceted functions of the gut microbiota. In summary, the gut microbiota's composition is diverse and individualized, and its functions include fermentation of dietary components, nutrient metabolism, immune system modulation, pathogen prevention, and potential impacts on mental health through the gut-brain axis. Understanding the intricacies of the gut microbiota is crucial for appreciating its function in preserving general health and exploring therapeutic interventions for various health conditions. Probiotics are a type of good microbe that can improve immunity and control the makeup of the intestinal flora. By preserving the intestinal epithelium, preventing pathogens from sticking to the intestinal surface, and adjusting and developing the immune system appropriately, probiotics can enhance host immunity (9).

DIVERSITY AND DYNAMICS

The gut is home to an incredibly diverse array of microbial species, collectively known as the gut microbiota. This intricate ecosystem comprises bacteria, viruses, fungi, and archaea, and its composition can vary widely among individuals. The predominant microbial inhabitants are bacteria, with thousands of different species identified.

Some of the major bacterial phyla found in the gut include Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. At the clinical level, products containing tyndallized probiotic strains have had a role in gastrointestinal diseases, including bloating and infantile colic in combination with mucosal protectors and diarrhoea. Heat-inactivated probiotics could also have a role in the management of dermatological or respiratory allergic diseases (10).

Within these phyla, specific genera and species further contribute to the richness of the gut microbiota. For example, the Firmicutes phylum includes bacteria such as *Clostridium*, *Lactobacillus*, and *Ruminococcus*, while the Bacteroidetes phylum encompasses genera like *Bacteroides* and *Prevotella*. Actinobacteria, another significant phylum, includes the genus *Bifidobacterium*, which is often considered beneficial for gut health. The diversity of the gut microbiota is influenced by various factors, including genetics, diet, lifestyle, and environmental exposures. The factors are discussed below and depicted in fig 2.

- 1. Diet:** The gut microbiota is greatly impacted by the variety and the type of food consumed. Diets rich in fibre, fruits, and vegetables tend to promote microbial diversity, while diets high in saturated fats and sugars may contribute to dysbiosis.
- 2. Antibiotic Use:** Antibiotics can disrupt the balance of the gut microbiota by affecting both beneficial and harmful bacteria. Prolonged or frequent antibiotic use may lead to a decrease in microbial diversity and the overgrowth of antibiotic-resistant strains.
- 3. Age:** The gut microbiota evolves over the lifespan, with distinct microbial profiles in infancy, adulthood, and old age. Aging is associated with changes in microbial diversity and composition, influenced by factors such as diet, immune function, and overall health.
- 4. Genetics:** Host genetics can impact gut microbiota's makeup. However, the extent to which genetics determines microbial profiles is still an area of active research.
- 5. Lifestyle and Environmental Factors:** Factors such as stress, physical activity, and exposure to environmental pollutants can

impact the gut microbiota. Stress, for example, may change the microbiota's composition.

6. **Diseases and Medical Conditions:** Various health conditions, such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and metabolic disorders, can alter the composition of the gut microbiota. Conversely, an imbalanced microbiota may contribute to the development or exacerbation of certain diseases (11).

7. **Host Immune System:** The immune system of the host is essential for maintaining the balance of the gut microbiota. Immune responses can shape the composition of the microbiota and help prevent the overgrowth of harmful pathogens.

Understanding how these factors interact and influence the gut microbiota is essential for unraveling the complexities of this dynamic ecosystem and developing strategies to promote a healthy microbial balance. Research in this field continues to provide insights into the intricate relationships between the host and its microbiota (12).

FUNCTIONS OF GUT MICROBIOTA

The gut microbiota plays pivotal roles in various physiological processes, contributing significantly to digestion, metabolism, and immune function (13).

1. **Digestion:**

Fermentation of Dietary Fibers: The gut microbiota specializes in fermenting complex carbohydrates and dietary fibers that are resistant to digestion in the upper gastrointestinal tract. This fermentation process results in the production of short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, which serve as an energy source for the host.

Breakdown of Complex Carbohydrates: Certain bacteria in the gut microbiota have enzymes that can break down complex carbohydrates into simpler compounds that the host can absorb and utilize.

2. **Metabolism:**

Short-Chain Fatty Acid Production: SCFAs, produced during the fermentation of dietary fibers, contribute to host metabolism. They can be absorbed into the bloodstream

and used as an energy source for various tissues, including the colon cells.

Vitamin Synthesis: Some members of the gut microbiota are capable of synthesizing vitamins, particularly B vitamins (e.g., B12, folate) and vitamin K. These synthesized vitamins are absorbed and contribute to the host's overall nutritional status (14).

3. **Immune function:**

Development and Regulation of the Immune System: The microbiota in the gut is essential for the development and regulation of the immune system. Exposure to diverse microorganisms helps educate the immune system, enabling it to distinguish between harmful pathogens and harmless antigens.

Maintenance of Intestinal Barrier Integrity: By keeping the intestinal barrier intact, the gut microbiota helps to keep dangerous compounds out of the circulation. This barrier function is crucial for immune defense and overall health.

Competitive Exclusion of Pathogens: Beneficial bacteria in the gut compete with potential pathogens for resources and attachment sites, limiting the growth and colonization of harmful microorganisms.

Immune Modulation: The gut microbiota can modulate immune responses, influencing the balance between pro-inflammatory and anti-inflammatory signals. Dysregulation of this balance has been implicated in various immune-related conditions.

Understanding the intricate interactions between the gut microbiota and these physiological processes highlights its integral role in maintaining overall health. Imbalances or disruptions in the gut microbiota, known as dysbiosis, have been associated with a range of health conditions, emphasizing the importance of promoting and maintaining a healthy and diverse microbial community (15).

MECHANISM OF ACTION OF PROBIOTICS

Through four primary mechanisms—pathogen competitive exclusion, improved intestinal barrier function, host body immunomodulation, and neurotransmitter production—probiotics may have a favourable effect on human health. Probiotics

make it harder for infections to survive in the gut by competing with them for resources and receptor-binding sites. By generating compounds including organic acids, hydrogen peroxide, bacteriocins, and short chain fatty acids (SCFA), probiotics also have anti-microbial properties that reduce harmful bacteria in the digestive tract.




Fig.1 (Illustrates the presence of microbiota in gut)




Fig.3 Functions of gut microbiota

Moreover, probiotics improve intestinal barrier function by stimulating the production of mucin proteins, regulating the expression of tight junction proteins such as occludin and claudin-1, and modulating the immune response in the gut. The mechanism is depicted below in Figure 4.




Fig.2 Factors affecting influencing gut microbiota




Fig.4 Mechanism of action probiotics

Source-<https://www.frontiersin.org/articles/10.3389/fmicb.2023.1216674/full>

METABOLIC EFFECTS

Numerous research has shown how probiotics can help with metabolic illnesses. A study has demonstrated the impact of fermented dairy products, particularly when combined with specific strains of lactic acid bacteria, on serum cholesterol levels. For example, it has been discovered that a very small amount of *Lactobacillus fermentum* KC4b dry culture may extract 14.8 mg of cholesterol from the culture medium. Additionally, lactobacilli are crucial for the breakdown of bile salts into bile acids in the colon, which prevents the development of micelles.

In vivo lipid metabolism is enhanced, and lipid peroxidation is decreased by probiotics. Weeks of probiotic supplementation enhanced the immune response without releasing inflammatory cytokines, delaying the onset of systemic inflammatory diabetes caused by inflammation (16). There is evidence to suggest that variations in the gut microbiota's composition may exist before childhood obesity develops. In addition to its well-known benefits for gastrointestinal health and cardiovascular disorders, this review has demonstrated the potential of probiotics to mediate metabolic illnesses through the positive modulation of multiple physiological systems (17).

APPLICATIONS OF PROBIOTICS IN HEALTH

Gut Microbiota Modulation:

The gut microbiota, comprising trillions of microorganisms, plays a central role in maintaining immune homeostasis, metabolic regulation, and gastrointestinal health. Probiotics contribute to gut microbiota modulation by enhancing microbial diversity, restoring beneficial bacterial populations, suppressing pathogenic microorganisms, and reducing intestinal inflammation (18). Through these actions, probiotics help maintain microbial balance and support overall host health.

Immune System Regulation:

Probiotics exert significant immunomodulatory effects by interacting with immune cells in the gut-associated lymphoid tissue (GALT) and systemic

immune pathways. They promote balanced immune responses by stimulating anti-inflammatory cytokine production, regulating pro-inflammatory pathways, and enhancing both innate and adaptive immunity. This immune regulation may reduce excessive inflammatory responses and improve host defense mechanisms.

Intestinal Barrier Function:

Maintenance of intestinal barrier integrity is a critical function of probiotics. They enhance tight junction protein expression, stimulate mucin production, and strengthen epithelial cell defenses, thereby reducing intestinal permeability. A well-maintained gut barrier prevents translocation of harmful pathogens, toxins, and inflammatory mediators into systemic circulation, reducing the risk of inflammatory and metabolic disorders.

Inflammatory Bowel Diseases (IBD):

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are characterized by chronic gastrointestinal inflammation and microbial dysbiosis. Certain probiotic strains, particularly *Lactobacillus* and *Bifidobacterium* species, have shown potential in reducing intestinal inflammation, improving microbial balance, and alleviating disease symptoms in some patients (19). However, strain-specific efficacy and disease severity must be considered.

Irritable Bowel Syndrome (IBS):

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. Probiotics may improve IBS symptoms by modulating gut motility, reducing visceral hypersensitivity, balancing gut microbiota, and lowering mucosal inflammation. Emerging evidence suggests that specific probiotic formulations may be beneficial in symptom management.

Rheumatoid Arthritis (RA):

Emerging studies suggest that probiotics may influence systemic inflammatory diseases such as rheumatoid arthritis (RA) by modulating gut microbiota composition and systemic immune responses. Although current evidence remains preliminary,

probiotic-induced reduction in inflammatory mediators may offer supportive therapeutic potential in autoimmune and inflammatory conditions (8).

Dermatological Conditions:

The gut–skin axis has gained increasing attention in probiotic research. Probiotics may contribute to the management of inflammatory skin disorders such as eczema, atopic dermatitis, and psoriasis by regulating immune responses, reducing systemic inflammation, and improving skin barrier health.

Metabolic Inflammation:

Chronic low-grade inflammation is a hallmark of metabolic disorders including obesity, insulin resistance, and type 2 diabetes mellitus. Probiotics may improve metabolic health by modulating energy metabolism, reducing inflammatory cytokines, enhancing insulin sensitivity, and influencing lipid metabolism. Their role in metabolic disease management is promising but requires further clinical validation.

Neuroinflammation and Mental Health:

The gut–brain axis represents a bidirectional communication system linking gut microbiota with neurological and psychological health. Emerging evidence suggests that probiotics may influence neuroinflammation, neurotransmitter production, and stress-related pathways, thereby potentially supporting the management of depression, anxiety, and other neuropsychiatric disorders. While results are encouraging, further mechanistic and clinical studies are necessary (20).

CHALLENGES IN PROBIOTIC RESEARCH

Despite substantial advancements in probiotic science, several challenges continue to limit the precise understanding of probiotic mechanisms and their optimal therapeutic application. One of the primary challenges is the extensive heterogeneity among probiotic strains. The term “probiotics” encompasses a wide range of microorganisms with distinct biological properties, making it difficult to generalise health benefits across different strains. Strain-specific variations in colonisation capacity, metabolite production, and host

interaction complicate the identification of the most effective probiotics for specific diseases or clinical conditions.

Another major limitation is the considerable interindividual variability in probiotic response. Host genetics, age, baseline gut microbiota composition, dietary patterns, environmental exposures, medication use, and lifestyle factors can significantly influence probiotic efficacy. As a result, therapeutic outcomes are often inconsistent across populations, highlighting the need for personalized probiotic strategies.

Methodological inconsistencies across clinical and experimental studies further hinder progress in the field. Variations in probiotic strain selection, dosage, formulation, treatment duration, and delivery systems create difficulties in comparing results and establishing standardized clinical recommendations. Uniform protocols for strain identification, viability assessment, and outcome measurement are essential to improve reproducibility and evidence quality.

The complexity and dynamic nature of the gut microbiota also present substantial scientific challenges. The gut ecosystem involves intricate interactions among microorganisms, host immune pathways, metabolic networks, and environmental factors, making it difficult to establish direct causal relationships between probiotic administration and specific health outcomes. Understanding these multifactorial interactions requires advanced multi-omics approaches, including metagenomics, metabolomics, and transcriptomics.

Regulatory limitations further complicate probiotic research and commercialization. In many regions, probiotics are regulated primarily as dietary supplements or functional foods rather than pharmaceutical agents, resulting in variable standards for product quality, safety, strain specificity, and clinical validation. This regulatory inconsistency may affect product reliability and consumer trust.

Additionally, concerns regarding probiotic viability, stability during storage, survival through the gastrointestinal tract, and long-term safety remain important considerations.

Ensuring that probiotic strains remain biologically active until reaching their target site is essential for therapeutic success.

Addressing these scientific, methodological, and regulatory challenges is critical for advancing probiotic research. Future progress will depend on rigorous strain-specific investigations, standardised clinical trial designs, improved regulatory frameworks, and the development of personalised microbiome-based interventions to fully harness the therapeutic potential of probiotics in human health (21).

FUTURE DISCUSSIONS

The field of probiotic research is rapidly advancing, with emerging innovations expected to significantly enhance the precision, efficacy, and therapeutic scope of probiotic interventions. Future developments are increasingly focused on personalised medicine, advanced delivery technologies, and next-generation microbiome modulation strategies.

Personalised Probiotics

As our understanding of individual gut microbiota composition deepens, personalised probiotics are gaining considerable attention as a promising approach for the future. Individual variations in microbiome diversity, genetics, diet, lifestyle, and disease susceptibility influence probiotic responsiveness, suggesting that a universal probiotic strategy may not be equally effective for all individuals. Personalised probiotic therapy involves analysing an individual's microbiome profile to identify microbial imbalances or deficiencies and designing targeted probiotic formulations accordingly. This precision-based strategy may improve therapeutic efficacy, reduce interindividual variability, and optimize outcomes in conditions such as gastrointestinal disorders, metabolic diseases, immune dysfunction, and neuropsychiatric conditions.

Smart Delivery System

One of the major limitations of probiotic therapy is ensuring microbial survival through the acidic gastric environment and successful colonization of the intestines. Emerging advancements in nanotechnology, microencapsulation, and targeted delivery

systems offer promising solutions to this challenge. Techniques such as polymer-based encapsulation, bioengineered coatings, and controlled-release formulations can protect probiotic organisms from gastric degradation and ensure their release at specific intestinal sites. These innovations may improve probiotic stability, viability, and therapeutic effectiveness.

Synbiotics, postbiotics, and microbiome engineering

Future probiotic research is also expanding beyond conventional probiotics toward synbiotics (combined probiotics and prebiotics), postbiotics (bioactive metabolites or microbial byproducts), and microbiome engineering. Synbiotics may enhance probiotic colonization by providing selective nutritional support, while postbiotics may offer therapeutic benefits without requiring live organisms, potentially improving safety and stability. Microbiome engineering, including genetically modified probiotics and precision microbial therapeutics, represents an advanced frontier with potential applications in disease-specific treatment.

Muti-omics and artificial intelligence integration

The integration of metagenomics, metabolomics, transcriptomics, and artificial intelligence (AI) is expected to revolutionize probiotic research. These technologies can improve understanding of host-microbiome interactions, identify predictive biomarkers, and support the design of personalized probiotic interventions based on real-time biological data.

In summary, the future of probiotic research lies in precision-targeted, technologically advanced, and evidence-based strategies. Continued interdisciplinary research will be essential to translate these innovations into clinically effective applications and maximize the therapeutic potential of probiotics in personalized healthcare (22).

CONCLUSION

Current evidence underscores the significant role of probiotics in modulating gut microbiota composition, maintaining intestinal homeostasis, and promoting overall human health. By enhancing microbial diversity, strengthening intestinal barrier

integrity, producing beneficial metabolites, and regulating immune responses, probiotics contribute substantially to gastrointestinal function and systemic well-being. Their therapeutic potential has been increasingly recognized in the management of gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea, while emerging evidence also suggests broader applications in metabolic health, immune modulation, dermatological conditions, and neuropsychiatric disorders through the gut-brain axis. Despite these promising benefits, probiotic efficacy is highly strain-specific and influenced by individual host factors, emphasizing the need for personalized and evidence-based therapeutic approaches. Challenges related to strain heterogeneity, methodological standardization, regulatory frameworks, and mechanistic clarity remain significant barriers to widespread clinical implementation. Future advancements in personalized probiotics, synbiotics, postbiotics, microbiome engineering, and smart delivery technologies are expected to expand the precision and effectiveness of probiotic interventions. Continued integration of multi-omics technologies and well-designed clinical trials will be essential to establish standardized guidelines and optimize probiotic applications across diverse populations.

Overall, probiotics represent a promising, non-invasive, and evolving strategy for preventive and therapeutic healthcare. This review contributes to the growing body of scientific knowledge by providing a comprehensive overview of the mechanisms, applications, challenges, and future directions of probiotics in shaping gut microbiota and influencing human health.

REFERENCES

1. Alzaidi RE, Al-Mozan HD, Alrikabi NJ. Eukaryotic probiotic *saccharomyces boulardii* application in clinical trails: A review. *Int J Pharm Qual Assur*. 2020;11(1).
2. Williams NT. Probiotics. *Am J Heal Pharm*. 2010 Mar;67(6):449–58.
3. Madsen KL. The Use of Probiotics in Gastrointestinal Disease. *Can J Gastroenterol*. 2001;15(12):817–22.
4. Obaid SM, Shaker AH, Al-Dulaimi FKY. The Role of *Saccharomyces boulardii* as a Probiotic in Mice with Celiac Disease. *Int J Drug Deliv Technol*. 2022;12(1).
5. Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, Pogodziński D. Nutrition and Supplementation in Ulcerative Colitis. *Nutrients*. 2022 Jun;14(12):2469.
6. Gupta V, Garg R. PROBIOTICS. *Indian J Med Microbiol*. 2009 Jul;27(3):202–9.
7. Wilson AS, Koller KR, Ramaboli MC, Nesengani LT, Ocvirk S, Chen C, et al. Diet and the Human Gut Microbiome: An International Review. *Dig Dis Sci*. 2020 Mar;65(3):723–40.
8. Seely KD, Kotelko CA, Douglas H, Bealer B, Brooks AE. The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis. *Int J Mol Sci*. 2021 Aug;22(17):9452.
9. Wieërs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy J-M, Dequenne I, et al. How Probiotics Affect the Microbiota. *Front Cell Infect Microbiol*. 2020 Jan;9.
10. Piqué N, Berlanga M, Miñana-Galbís D. Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview. *Int J Mol Sci*. 2019 May;20(10):2534.
11. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol*. 2018 Feb;11(1):1–10.
12. Vandenplas Y, Carnielli VP, Ksiazek J, Luna MS, Migacheva N, Mosselmans JM, et al. Factors affecting early-life intestinal microbiota development. *Nutrition*. 2020 Oct;78:110812.
13. Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. *Mol Nutr Food Res*. 2017 Jan;61(1).
14. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain

15. Communication. Front Endocrinol (Lausanne). 2020 Jan;11.
16. Jandhyala SM. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787.
17. Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC. Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health. Cells. 2023 Jan;12(1):184.
18. Oniszczyk A, Oniszczyk T, Gancarz M, Szymańska J. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases. Molecules. 2021 Feb;26(4):1172.
19. Tojo R. Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163.
20. Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020 Dec;113(12):2019–40.
21. Mörk S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the Microbiota-Gut-Brain Axis: Focus on Psychiatry. Curr Nutr Rep. 2020 Sep;9(3):171–82.
22. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019 May;25(5):716–29.
23. Sarao LK, Arora M. Probiotics, prebiotics, and microencapsulation: A review. Crit Rev Food Sci Nutr. 2017 Jan;57(2):344–71.